Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-06-02

Clinical Trial Update: Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease [Phase 2]

View source ↗

Summary

Extension study evaluating safety and efficacy of pasireotide in participants with Cushing's disease (Phase 2; completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pasireotide (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cushing Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-06-02